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Introduction
To begin their journey along the biosynthetic/secretory pathway, 
proteins that have entered the ER and are destined for the Golgi 
apparatus or beyond must first exit the ER (Gorelick and Shugrue, 
2001;  Ellgaard  and  Helenius,  2003;  Mancias  and  Goldberg, 
2005; Hughes and Stephens, 2008). ER export is mediated by 
vesicle formation at specialized ER domains known as the ER 
exit sites (ERES) by the coat protein II (COPII) complex. The 
first mechanistic understanding of the function of various com-
ponents of COPII pertaining to vesicle formation came from 
studies on the yeast system (Kuehn et al., 1998). We now have a 
fairly good understanding of the molecular and structural inter-
actions that drive COPII assembly (Tang et al., 2000; Gürkan   
et al., 2006; Bi et al., 2007; Kirk and Ward, 2007; Fromme and 
Schekman, 2008; Stagg et al., 2008). COPII subunits must first 
be recruited to the correct sites on the ER membrane, i.e., that of 
the ERES. The COPII coat is formed through sequential binding 
of three cytosolic components, a small GTPase Sar1 (Nakano 
and Muramatsu, 1989; Barlowe et al., 1993), the Sec23/Sec24 
heterodimer complex (Hicke et al., 1992), and the Sec13/Sec31 
heterotetramer complex (Salama et al. 1993) to the ERES. The 
sequence of COPII protein assembly was established by the se-
quential addition of yeast COPII components to an in vitro ER 
vesicle budding assay. This order of assembly was subsequently 
confirmed in mammalian cells (Barlowe et al., 1994; Kuge et al., 
1994; Aridor et al., 1995, Lee et al., 2004). Even though COPII 
vesicle formation could be minimally reconstituted using puri-
fied yeast COPII proteins (Matsuoka et al., 1998), additional 
regulatory factors such as Sec16p (Espenshade et al., 1995;   
Gimeno et al., 1996; Shaywitz et al., 1997; Supek et al., 2002) 
and Sed4p (Gimeno et al., 1995; Saito-Nakano and Nakano, 
2000) were found to contribute to the rate and efficiency of   
COPII-mediated protein export from the ER.
For each of the yeast COPII genes identified, there exist at 
least two or more homologous forms in mammals (Barlowe, 
2003). The presence of multiple isoforms in higher organisms 
brings about combinatorial diversity for COPII vesicle forma-
tion, indicating a greater range of complexity in the regulation 
of COPII-mediated protein export. Therefore, a comprehensive 
C
oat protein II (COPII)–mediated export from the 
endoplasmic reticulum (ER) involves sequential re-
cruitment of COPII complex components, includ-
ing the Sar1 GTPase, the Sec23/Sec24 subcomplex, and 
the  Sec13/Sec31  subcomplex.  p125A  was  originally 
identified as a Sec23A-interacting protein. Here we dem-
onstrate that p125A also interacts with the C-terminal re-
gion  of  Sec31A.  The  Sec31A-interacting  domain  of 
p125A is between residues 260–600, and is therefore a 
distinct  domain  from  that  required  for  interaction  with 
Sec23A. Gel filtration and immunodepletion studies sug-
gest that the majority of cytosolic p125A exists as a ter-
nary  complex  with  the  Sec13/Sec31A  subcomplex, 
suggesting that Sec 13, Sec31A, and p125A exist in the 
cytosol  primarily  as  preassembled  Sec13/Sec31A/
p125A heterohexamers. Golgi morphology and protein 
export from the ER were affected in p125A-silenced cells. 
Our  results  suggest  that  p125A  is  part  of  the  Sec13/
Sec31A subcomplex and facilitates ER export in mamma-
lian cells.
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p125A exists as part of mammalian 
Sec13/Sec31 subcomplex in the cytosol
Sec13 (33 kD) and Sec31A (140 kD) are believed to exist in the 
cytosol as heterotetramer and have a predicted combined molec-
ular weight of 370 kD. However, the Sec13/Sec31 complex 
has been reported to be fractionated to higher molecular weight 
regions of 600–700 kD (Salama et al., 1993, 1997; Shugrue   
et al., 1999; Tang et al., 2000; Kim et al., 2001; Lederkremer et al., 
2001). Biochemical and electron microscopy studies indicate 
that the heterotetramer complex exists as an elongated rod-like 
understanding of ER export in mammalian cells would depend 
on detailed biochemical and functional characterization of 
mammalian COPII proteins and their regulatory proteins.
The Sec13/Sec31 subcomplex is the last of the COPII 
components to be recruited onto membranes before vesicle for-
mation, and may be linked to components of regulatory mecha-
nisms that govern ER exit. We have previously shown that rat 
liver cytosol depleted of proteins that could potentially interact 
with the C-terminal fragment of Sec31A was defective in ER-
Golgi transport of vesicular stomatitis virus (VSV) G protein 
(VSVG) in a semi-intact cell assay (Tang et al., 2000). This ob-
servation indicates that a cytosolic factor(s) sequestered by the 
C-terminal fragment of Sec31A is likely important for ER ex-
port of VSVG.
p125A was first described as a Sec23-interacting periph-
eral protein of 125 kD with phospholipase A1 homology (Tani   
et al., 1999) and is enriched in the ERES, but the functional   
importance is unknown (Shimoi et al., 2005). The mammalian 
genome contains a p125A paralogue, p125B, which lacks the 
proline-rich N-terminal domain (1–372 residues) that is required 
for Sec23 interaction. The sequence homology is confined to   
region of residues 373–628 of p125A having an overall 52%   
sequence identity with the homologous region of p125B. p125B 
does not interact with Sec23 and its function is unclear, although 
it is a new member of the phosphatidic acid–preferring phospho-
lipase A1 family (Nakajima et al., 2002). p125A was recruited to 
the ERES in an active Sar1p-dependent manner. Overexpression 
of p125A causes ERES clustering at the perinuclear region   
(Tani et al., 1999; Shimoi et al., 2005). Our results here show 
that p125A is a Sec31A-interacting protein and likely part of a 
Sec13/Sec31A/p125A heterohexameric complex that facili-
tates ER-Golgi transport.
Results
p125A as a Sec31A-interacting protein
Our previous study showed that the C-terminal 180-residue 
region of Sec31A expressed as a GST fusion protein (GST-
Sec31A) inhibited in vitro transport of VSVG from the ER to 
the Golgi (Tang et al., 2000). One possible explanation is that 
GST-Sec31A sequesters important protein(s) that interact with 
endogenous Sec31A. To explore this hypothesis, GST-Sec31A 
was  used  in  pull-down  experiments  to  identify  possible 
Sec31A-interacting proteins. As shown in Fig. 1 A, several 
polypeptides from the rat liver cytosol were retained by im-
mobilized GST-Sec31A (lane 3) but not by GST (lane 2). Mass 
spectrometric analysis revealed that one of the bands is p125A 
(as indicated). Because p125A was originally identified as an 
interacting protein for Sec23A (Tani et al., 1999), we subse-
quently focused on its interaction with Sec31A and the func-
tional relevance of such an interaction. Coimmunoprecipitation 
experiments  validated  the  interaction  between  Sec31A  and 
p125A (Fig. 1 B). When GFP-Sec31A was coexpressed with 
myc-p125A, antibodies against myc can efficiently coimmuno-
precipitate GFP-Sec31A (lanes 2 and 5). The coimmunopre-
cipitation  is  dependent  on  the  coexpression  of  myc-125A 
(lanes 3 and 6).
Figure 1.  p125A binds to Sec31A. (A) GST-Sec31A and GST immobilized 
onto glutathione beads were incubated with rat liver cytosol and proteins 
retained on the beads were eluted and resolved on a 7% SDS-PAGE gel. 
Distinct bands were cut out and subjected to protein identification by mass 
spectrometry. Arrow indicates mammalian p125A with the identified pep-
tide sequences shown. (B) myc-p125A and GFP-Sec31A were exogenously 
expressed in HEK293 cells either singly or in combination as indicated. 
Cell lysates were prepared and subjected to immunoprecipitation by either 
anti-myc (9E10) antibodies or control mouse IgG. The samples (together 
with 5% starting materials as controls) were resolved by SDS-PAGE and 
transferred to PVDF and immunoblotted using antibodies against GFP and 
myc. Molecular size markers are in kD.3 of 15 p125 as part of Sec13/Sec31 subcomplex in ER-Golgi transport • Ong et al.
p125A in immunoblot (Fig. 2 A) and by immunolabeling (see 
Fig. 4 A). As shown in Fig. 2 B, the majority of p125A coeluted 
with Sec31A and Sec13 in fractions B4 to B7, which corre-
sponds to 600–700 kD in size as marked by thyroglobulin   
(669 kD). Similarly, the majority of Sec31A and Sec13 are present 
in these fractions, with some Sec13 also being detected in low 
molecular  weight  fractions  (B14–B15).  Consistent  with  pub-
lished data (Mizoguchi et al., 2000), p125A did not cofractionate 
with Sec23A. Most of Sec23A was eluted in fractions B7 to 
B11, which is closer to the size of apoferritin (400 kD). If two 
molecules of p125A are associated with Sec13/Sec31A hetero-
tetramer, then the estimated size of the complex will be 600 kD. 
structure (Lederkremer et al., 2001; Matsuoka et al., 2001; Stagg 
et al., 2006; Fath et al., 2007), which may be responsible for 
them to fractionate at a higher molecular weight in gel filtration 
(Siegel and Monty, 1966). Additionally, association of other pro-
teins with this heterotetrameric complex may also contribute to 
this observation. Because p125A was pulled down from rat liver 
cytosol by GST-Sec31A, p125A may be part of this Sec13/
Sec31A complex and should coelute in similar fractions with 
Sec13 and Sec31A in a gel filtration assay. To facilitate our 
studies on endogenous p125A, we have raised rabbit anti-
bodies using a recombinant fragment covering residues 500–758 
of p125A. These polyclonal antibodies react specifically with 
Figure 2.  p125A exists as a ternary complex with the Sec13/Sec31A heterotetramer in the cytosol. (A) Characterization of p125A antibodies. Residues 
500–758 of p125 were expressed as fusion protein with GST (GST-p125A) and used to raise rabbit antibodies. Affinity-purified antibodies were used for 
immunoblot analysis. 30 µg of HeLa cell (lanes 1, 3, and 5) and HEK293 cell lysate (lanes 2, 4, and 6) were loaded per lane. The lysates were resolved 
on SDS-PAGE, transferred to PVDF membrane, and then subjected to immunoblot analysis using anti-p125A antibodies. For the second and third panels, 
anti-p125A antibodies were preincubated with 500 µg of recombinant GST-Bet3 and GST-p125A, respectively. (B) p125A fractionated with Sec31A and 
Sec13 in gel filtration. HeLa cell cytosol was subjected to gel filtration in Superose 6 at a flow rate of 0.3 ml/min. Fractions (0.6 ml each) were collected 
and then TCA precipitated. The proteins were subjected to SDS-PAGE and transferred to PVDF and immunoblotted using antibodies against Sec31A, 
p125A, Sec23A, and Sec13 as indicated. The arrows indicate the fractions in which the molecular weight markers peaked. (C) Sec31A is co-immuno-
depleted with p125A. Cytosol was prepared from HEK293 cells transfected to express HA-p125A. The cytosol was subjected to three consecutive cycles 
of immunodepletion using anti-HA or control anti-GFP antibody-conjugated beads. One tenth of the cytosol was collected and TCA precipitated after 
each round of immunodepletion. The proteins (along with the cytosol before immunodepletion) were subjected to SDS-PAGE and transferred to PVDF and   
immunoblotted using antibodies against HA, Sec31A, p125A, Sec23A, and Rab8. Sec31A and total p125A were efficiently and proportionally depleted 
along with HA-p125A. (D) p125A exists in a multimeric form. myc-p125A and HA-p125A were exogenously expressed in transfected HEK293 cells either 
singly or in combination as indicated. Cell lysates were subjected to immunoprecipitation with anti-myc (lanes 4–6), anti-HA (lanes 7–9), and control mouse 
IgG (lanes 10–12). The immunoprecipitates, along with the starting materials, were resolved on SDS-PAGE and analyzed by immunoblot with antibodies 
against myc, HA, Sec31A, and Sec23A. Molecular size markers are in kD.JCB    of 15
that HA-p125A may interact with endogenous p125A because 
HA-p125A, being only 3 kD larger, was not resolvable from the 
endogenous p125A by SDS-PAGE. On the other hand, Sec23A, 
which is known to interact with p125A (Tani et al., 1999), was 
not immunodepleted as significantly as Sec31A and total p125A, 
which is consistent with the earlier result that it fractionated dif-
ferently from p125A in the cytosol. These results imply that 
Sec23A and p125A probably do not interact in the cytosol, and 
their  interaction  may  occur  preferentially  on  the  membrane. 
Rab8 (Huber et al., 1993) was used as a negative control.
It is thus conceivable that the majority of Sec13/Sec31 exists as 
a stable heterohexameric complex with p125A in the cytosol.
An immunodepletion experiment was performed using   
cytosol prepared from cells stably expressing HA-tagged p125A. 
As shown in Fig. 2 C, HA-p125A could be efficiently depleted 
after three consecutive immunoprecipitation steps. Interestingly, 
the levels of endogenous Sec31A and total p125A were also pro-
portionally reduced, suggesting that exogenously expressed   
HA-p125A and endogenous Sec31A exist in the same protein 
complex in the cytosol. The reduced level of total p125A implies 
Figure 3.  Residues 260–600 of p125A are sufficient for binding to Sec31A. (A) a schematic illustration of p125A deletion constructs. cDNA fragments encod-
ing various mutants were generated by PCR and validated by sequencing. The fragments were digested with SalI and NotI and then subsequently cloned into 
pDmyc-neo. KIAA0725p, the homologue of p125A, also known as myc-p125B (Nakajima et al., 2002), is also indicated. (B) myc-p125A deletion constructs 
were transfected into HEK293 cells. Cell lysates were prepared and subjected to pulldown using immobilized GST-Sec31A and GST. Proteins retained by the 
beads, along with cell lysates, were subjected to SDS-PAGE, transferred to PVDF membrane, and immunoblotted using anti-myc antibody. Red asterisk indicates 
the expected sizes of the various HA-tagged mutants; red hash indicates the smallest fragment that could be pulled down by GST-Sec31A. Solid red triangle 
indicates GST-Sec31A, and the empty red triangle represents GST. b, d, and f are Ponceau staining of the immunoblots. Molecular size markers are in kD.5 of 15 p125 as part of Sec13/Sec31 subcomplex in ER-Golgi transport • Ong et al.
vesicular structures enriched in the perinuclear region with 
some being scattered around the cell periphery (Fig. 4 A, a).
The labeling was abolished by prior incubation of the antibodies 
with the recombinant antigen (Fig. 4 A, g), but not by prior in-
cubation with unrelated GST-Bet3 (Fig. 4 A, d). Double label-
ing using rabbit anti-p125A and mouse anti-Sec31A antibodies 
revealed that the majority of p125A-labeled vesicular struc-
tures are also positive for Sec31A (Fig. 4 B). The colocaliza-
tion of p125A with Sec31A is very extensive and is consistent 
with the notion that p125A interacts with Sec31A not just in 
the cytosol, but also on specific membranes. These results sug-
gest that, like other COPII components, endogenous p125A is 
enriched in the ERES.
Live  imaging  of  cells  coexpressing  p125A-Cherry  and 
Sec31A-GFP  showed  that  they  are  extensively  colocalized   
(Fig. 4 C). p125A-Cherry and Sec31A-GFP are associated with 
each other quite stably over the observed period of 30 min   
(Fig. 4 D). The spotty ERES structures marked by Sec31A-GFP and 
p125A-Cherry were in constant motion and were sometimes 
observed to participate in homotypic fusion (illustrated by time-
lapse sequences in Fig. 4 E for the boxed region in Fig. 4 D). 
These results suggest that p125A functions in close association 
with COPII coat components.
p125A depletion by RNAi caused 
fragmentation and dispersion of the  
Golgi apparatus
To investigate the cellular role of p125A, RNAi was used to 
knock down its expression. As shown in Fig. 5 A, p125A was 
efficiently knocked down by p125A-specific siRNA (lane 1), 
whereas the levels of Sec31A, Sec23A, and Sec13 were not sig-
nificantly affected (lane 4). siRNA for Sec13 not only efficiently 
decreased the level of Sec13, but also significantly reduced the 
level of Sec31A (lane 3), suggesting that the stability of Sec31A 
might be dependent on its interaction with Sec13. Silencing 
Sec31A by its siRNA, however, did not significantly affect the 
level of Sec13 (lane 2). This is in agreement with the fraction-
ation data in Fig. 2 B, which showed that a substantial amount 
of Sec13 in the cytosol exists as low molecular weight (presum-
ably monomeric) forms.
The cellular distribution of Sec31A was noticeably affected 
in p125A-silenced cells, and vice versa (Fig. 5 B). In comparison 
to control cells treated with nontarget siRNA (panels a–c), upon 
p125A knockdown (panels d–f), Sec31A labeling in the peri-
nuclear region appeared more diffused (panel e). Furthermore, 
the background labeling for Sec31A (likely reflecting distribution 
of Sec31A in the cytosol) seemed increased in p125A knock-
down cells. In cells where Sec31A is silenced (panels g–i), p125A 
seemed to be more concentrated around the perinuclear region 
with an elevated background (likely cytosolic) labeling. p125A 
labeling in the peripheral vesicular structures was mostly reduced. 
These results indicate that the normal distribution of Sec31A   
and p125A in the ERES may be influenced by the presence of 
each other.
The role of p125A in maintaining normal Golgi structure 
was first investigated by examining the effect of its depletion   
on  the  distribution  of  the  Golgi  1,4-galactosyl  transferase 
The ability of anti-HA-p125A antibodies to also deplete 
total (and thus also endogenous) p125A suggests that more than 
one molecule of p125A is present in the complex with Sec31A, 
and that p125A may be able to interact with itself either directly 
or indirectly via interaction with Sec31A. Using two different 
epitope-tagged versions of p125A, reciprocal coimmunoprecipi-
tation experiments were performed. As shown in Fig. 2 D, when 
myc-p125A and HA-p125A were coexpressed (lane 2), antibodies 
against either myc (lane 5) or HA (lane 8) could recover both 
forms of tagged p125 in addition to the recovery of Sec31A and 
Sec23A from total cell lysate. HA-p125A, Sec31A, or Sec23A 
was  not  recovered  by  anti-myc  antibodies  when  myc-p125 
was not coexpressed (lane 6). Similarly, myc-p125A, Sec31A, 
or Sec23A was not recovered by anti-HA antibodies when HA-
p125 was not coexpressed (lane 7). These results suggest that 
some HA-p125A and myc-p125A are present in the same com-
plex with Sec31A. The coimmunoprecipitation of Sec23A with 
tagged p125A in this experiment suggests that a membrane-
bound pool of p125A was precipitated, implying that p125A is 
likely interacting simultaneously with Sec31 and Sec23 on the 
membrane in addition to self-interaction. These results suggest 
that Sec13, Sec31A, and p125A preferentially exist as a stable 
heterohexamer in the cytosol. Once recruited onto the mem-
brane, they can then engage the Sec23A/Sec24 subcomplex.
Residues 260–600 of p125A are mostly 
responsible for its interaction with Sec31A
To define the region of p125A that is responsible for its inter-
action  with  Sec31A,  expression  constructs  for  eight  different 
fragments of p125A (Fig. 3 A) were generated. Together with 
constructs expressing full-length p125A and p125B, they were 
subjected to pull-down assays using GST-Sec31A. As shown in 
Fig. 3 B, all proteins were successfully expressed (left panels). 
Consistently, myc-p125A (lane 1) but not myc-p125B (lane 10) 
was recovered by immobilized GST-Sec31A (middle panels).   
Deletion of its N-terminal 304 residues completely disrupted its   
interaction with Sec31A (lane 7), although this N-terminal 304-
residue region was not itself sufficient for Sec31A interaction 
(lane 2). Deletion of the N-terminal 100 or 200 residues did not 
affect the interaction (lanes 8 and 9, respectively). The N-terminal 
fragments consisting of residues 1–600 or 1–650 were retained by 
GST-Sec31A (lanes 3 and 4, respectively). Furthermore, the frag-
ment consisting of residues 260–600 was efficiently retained by 
GST-Sec31A (lane 6). Further deletion using this fragment re-
sulted in disruption of its ability to interact with Sec31A, suggest-
ing that residues 260–600 encompass the determinant for p125A 
to interact with Sec31A. Because a previous study has defined the 
region consisting of residues 135–250 as being responsible for 
p125A’s interaction with Sec23A (Mizoguchi et al., 2000), these 
results suggest that p125A interacts with Sec23A and Sec31A   
using different regions. As such, p125A may have the potential to 
interact with Sec23A and Sec31A simultaneously, which is con-
sistent with coimmunoprecipitation results (Fig. 2 D).
p125A is enriched in the ERES
Using rabbit antibodies against p125A for indirect immuno-
fluorescence microscopy, p125A labeling decorated numerous JCB    of 15
Figure 4.  p125A colocalizes extensively with Sec31A. (A) HeLa cells were fixed and labeled with anti-p125A antibodies (a, d, and g) and DAPI (b, e, 
and h). For the second (d–f) and third (g–i) panels, the antibodies were preincubated with 500 µg of recombinant GST-Bet3 and GST-p125A, respectively. 
The merged images are shown in c, f, and i. Bar, 10 µm. (B) HeLa cells were fixed and double-labeled with rabbit anti-p125A and mouse anti-Sec31A 
antibodies. Enlarged images of the boxed area are shown in the bottom panels. Bar, 10 µm. (C) HeLa cells were transfected to coexpress p125A-Cherry (a)   
and Sec31A-GFP (b). The live cells were imaged with a confocal microscope (Fluoview 1000; Olympus). Merged picture and DIC image are shown in   
c and d, respectively. Bar, 10 µm. (D) p125A- and Sec31A-positive structures are colocalized stably with each other over time, and undergo homotypic 
fusion. HeLa cells were transfected to coexpress p125A-Cherry and Sec31A-GFP. The cells were subjected to live-cell imaging. The vesicular structures of 
p125A-Cherry colocalize extensively with those of Sec31A-GFP over a period of at least 30 min (Video 1). Inset is enlarged in panels shown in E. Bar, 10 µm.   
(E) p125A-Cherry and Sec31A-GFP containing vesicular structures undergo homotypic fusion as indicated by the boxed areas (Video 2). Bar, 2 µm. of 15 p125 as part of Sec13/Sec31 subcomplex in ER-Golgi transport • Ong et al.
Figure 5.  Knockdown of p125A perturbs the structural organization of the early secretory pathway. (A) HeLa cells were transfected twice with ON-Target-
plus SMARTpool siRNA (Thermo Fisher Scientific) for p125A, Sec31A, Sec13, or nontarget control with a 24-h interval. 72 h after the initial transfection, 
cell lysates were prepared and resolved on SDS-PAGE, then subjected to immunoblot analysis using antibodies against Sec31A, p125A, Sec23A, Sec13, 
and actin. Molecular size markers are in kD. (B) HeLa cells silenced of p125A and Sec31A were double labeled with rabbit anti-p125A and mouse anti-
Sec31A antibodies. Bar, 10 µm. (C) HeLa cells stably expressing GT-GFP were silenced of p125A (left), Sec31A (center), and Sec13 (right). The cells were 
then processed for indirect immunofluorescence to view GT-GFP as well as p125A, Sec31A, and Sec13, respectively. Bar, 10 µm. (D) HeLa cells stably 
expressing GT-GFP were transfected with nontarget, p125A-, or Sec13-specific siRNA. The dispersion and fragmentation of the Golgi marked by GT-GFP 
were quantified using Cell^P software (Olympus). The open bar represents cells treated with nontarget siRNA, filled bar indicates p125A knockdown cells, 
and striped bar shows the Sec13 knockdown cells. n = 15; *, P < 0.0001; **, P < 0.0001.JCB   8 of 15
Before the addition of BFA, GT-GFP in control cells showed 
compact structures of the Golgi apparatus (Fig. 6 C, a). In the 
presence of BFA, GT-GFP was distributed to the ER (panel b). 
Upon removal and washout of BFA, GT-GFP was exported from 
the ER and became concentrated in the reassembled Golgi 
apparatus (panels c–f). 30 min after BFA removal, some GT-GFP 
was found concentrated in post-ER compartments (panel c) and 
clear Golgi localization of GT-GFP was seen after 45 min of   
removal (panel d). After 60 min (panels e and f), GT-GFP has   
essentially redistributed back to the compact Golgi structures.
ER export and distribution of GT-GFP back into mini-
Golgi structures were clearly delayed in p125A-silenced cells 
(Fig. 6 C, bottom panels). GT-GFP was initially localized to 
fragmented Golgi structures (panel g). Upon BFA treatment, as 
in control cells, GT-GFP was distributed to the ER (panel h). 
Even after 30–45 min, the majority of GT-GFP remained in the 
ER (panels I and j). Some noticeable amount of GT-GFP was 
seen in post-ER structures after 60 min (panel k). After an addi-
tional 30 min (90 min after BFA washout; panel i), GT-GFP was 
then redistributed back to the mini-Golgi structures. The extents 
of ER export observed at 60 min (panel k) in p125A-silenced 
cells were not as obvious and extensive as those observed at   
30 min in control cells (panel c), suggesting a delay of ER export 
of more than 30 min under these conditions. However, from the 
point of detectable ER export to Golgi redistribution, GT re-
distribution occurred at comparable kinetics (taking 30 min) 
in both control cells (from 30 to 60 min, panels c to e) and p125A-
silenced cells (from 60 to 90 min, panels k–l). These results 
suggest that the delay of Golgi redistribution in p125A-silenced 
cells is mainly at the point of ER export. Once exported, the rate 
of redistribution of GT to the Golgi apparatus in control cells 
and mini-Golgi in p125A-silenced cells is not significantly dif-
ferent. These results suggest that p125A plays an important role 
specifically in the ER export.
To corroborate a role of p125A in ER export, we moni-
tored the ER export and subsequent transport along the secre-
tory pathway of VSVG. A temperature-sensitive mutant of the 
VSVG (VSVG-tsO45) tagged with yellow fluorescent protein 
(VSVG-tsO45-YFP) was used. At the nonpermissive tempera-
ture, VSVG-tsO45-YFP is misfolded and accumulated in the 
ER. Upon shifting to the permissive temperature, VSVG-tsO45-
YFP folds properly, and is then exported to the Golgi, en route 
to the plasma membrane. These characteristics allow us to mon-
itor the synchronized transport of VSVG-tsO45-YFP along the 
secretory pathway.
We first looked at the distribution of p125A, Sec31A, and 
VSVG-tsO45-YFP during ER export. The majority of p125A 
and Sec31A was colocalized in structures characteristic of the 
ERES. Interestingly, a significant amount of VSVG-tsO45-YFP 
was found to be colocalized with some of these p125A- and 
Sec31A-positive ERES after a short period (5 min) of release 
from the nonpermissive temperature (Fig. 7 A), suggesting that 
p125A acts together with COPII in the ERES. We next moni-
tored the kinetics of export and subsequent transport of VSVG-
tsO45-YFP when p125A was silenced (Fig. 7 B). In control 
cells, VSVG-tsO45-YFP was clearly present in dispersed peri-
nuclear structures 5 min after release (panel c), and had reached 
(GT)-GFP (Schaub et al., 2006) (Fig. 5 C). HeLa cells stably 
expressing GT-GFP were used in this study. In control cells 
transfected with nontargeting siRNA, GT-GFP was distributed 
as  compact  structures  characteristic  of  the  Golgi  apparatus 
(panels k, o, and s). In cells silenced of p125A (panel m) or 
Sec13 (panel u), GT-GFP distribution was aberrant, and ap-
peared as fragmented vesicular structures that scattered more 
widely around the perinuclear region (panels m and u). Interest-
ingly, in Sec31A-silenced cells (panel q), the general distribu-
tion  of  GT-GFP  to  the  Golgi  apparatus  was  not  obviously 
altered. It was somewhat surprising that knockdown of Sec31A 
did not achieve a similar phenotype as Sec13 knockdown. One 
possibility is due to the presence of Sec31B, which shares 
47.3% identity to Sec31A and may be able to functionally com-
pensate for the loss of Sec31A (Shugrue et al., 1999; Tang et al., 
2000; Stankewich et al., 2006). The extent of Golgi dispersion 
in response to p125A and Sec13 knockdown was measured and 
seen to be significantly higher as compared with control cells 
(Fig. 5 D), suggesting that, like Sec13, p125A is essential for 
the maintenance of normal Golgi structure.
We next examined the distribution of markers for various 
subcompartments of the Golgi apparatus in p125A knock-
down  cells.  HeLa  cells  stably  expressing  mannosidase  II-GFP   
(ManII-GFP) were used for simultaneous labeling of three Golgi 
subcompartments: the trans-Golgi marked by endogenous GT 
(Schaub et al., 2006), the Golgi stack (or medial Golgi) marked 
by ManII-GFP (Velasco et al., 1993), and the cis-Golgi marked 
by endogenous GM130 (Marra et al., 2007). GT, ManII-GFP, 
and GM130 were generally colocalized in the compact Golgi 
apparatus in control cells (Fig. 6 A, a–d). Like GT-GFP, endog-
enous GT was dispersed into vesicular structures that spread 
widely when p125A was knocked down (panel e). Similar to 
GT-marked trans-Golgi, the medial-Golgi marked by ManII-
GFP (panel f) and cis-Golgi marked by GM130 (panel g) were 
also fragmented and dispersed into vesicular structures. Higher 
resolution images showed that the cis-Golgi and trans-Golgi are 
not completely colocalized but only partially overlapped (panel i). 
These results suggest that the knockdown of p125A fragmented 
the compact Golgi apparatus into many mini-Golgi structures, 
with each containing markers from all three Golgi subcompart-
ments. In spite of their apparent disconnection, these mini-Golgi 
fragments may still maintain their cis-to-trans organization. The 
Golgi fragmentation due to p125A knockdown can be rescued by 
overexpression of myc-p125A (Fig. 6 B). The result suggests that 
the phenotype produced by p125A knockdown was specific, 
and the observed Golgi fragmentation is indeed due to reduced 
levels of endogenous p125A.
ER export was retarded in  
p125A-silenced cells
Because COPII coat mediates ER export and p125A interacts 
with COPII components and is enriched in the ERES, p125A 
may act together with the COPII coat to facilitate ER export. To 
determine if p125A is involved in COPII-mediated ER export, 
the ER export of cells treated with p125A RNAi was examined. To 
assay for ER export, Golgi reassembly in response to brefeldin A 
(BFA) treatment and washout was measured in HeLa GT-GFP cells.  of 15 p125 as part of Sec13/Sec31 subcomplex in ER-Golgi transport • Ong et al.
VSVG-tsO45-YFP was present in fragmented mini-Golgi by   
30 min. After which, VSVG-tsO45-YFP was seen to be deliv-
ered to the plasma membrane (panels k–l). Because the most 
obvious delay for VSVG-tsO45-YFP transport is at the stage of 
ER export in p125A-silenced cells, these results further support 
a role for p125A in COPII-mediated ER export.
We also monitored VSVG-tsO45-YFP transport by a bio-
chemical approach (Fig. 7 C). VSVG-tsO45-YFP is a glycoprotein 
the Golgi complex by 15–30 min (panels c and d). At 60 min, 
VSVG-tsO45-YFP was seen to move via vesicular structures 
from the Golgi for delivery to the surface (panel e). By 120 min, 
most VSVG-tsO45-YFP had arrived at the plasma membrane 
(panel  f).  For  p125A-silenced  cells,  however, VSVG-tsO45-
YFP remained essentially in the ER after 5 min release (panel h). 
At 15 min upon release, VSVG-tsO45-YFP was then seen in 
perinuclear vesicular structures (panel i) and the majority of 
Figure 6.  The Golgi apparatus is fragmented into mini-Golgi structures in p125A-silenced cells. (A) HeLa cells stably expressing ManII-GFP were silenced 
of p125A and then double labeled using mouse anti-GM130 and rabbit anti-GT antibodies followed by viewing the distribution of trans-Golgi marked by 
GT, medial-Golgi marked by ManII-GFP, and cis-Golgi marked by GM130. Bar, 10 µm. (B) Exogenous expression of myc-p125A can rescue the dispersed 
Golgi phenotype in p125A-silenced cells. HeLa cells stably expressing GT-GFP were transfected twice with ON-Targetplus SMARTpool siRNA (Thermo 
Fisher Scientific) against p125A with a 24-h interval. 48 h after siRNA transfection, the cells were transfected again to express myc-p125A. At 72 h after 
the initial siRNA transfection, the cells were processed for indirect immunofluorescence microscopy to view GT-GFP and myc-p125A. Asterisk denotes a res-
cued cell expressing myc-p125A. Bar, 10 µm. (C) ER export is delayed in p125A-silenced cells. HeLa cells stably expressing GT-GFP were transfected twice 
either with nontarget or p125A siRNA. At 72 h after the initial transfection, the cells were treated with BFA (5 µg/ml) for 30 min to distribute GT-GFP into 
the ER. The cells were then washed and incubated in BFA-free warm medium for the indicated times, and samples were fixed for fluorescence microscopy 
to assay for ER-Golgi transport of GT-GFP. All of the images were taken at the same exposure and processed in parallel. Bar, 10 µm.JCB   10 of 15
Figure 7.  ER-Golgi transport of VSVG-tsO45-YFP is delayed in p125A-silenced cells. (A) HeLa cells were transfected with VSVG-tsO45-YFP and incubated 
at nonpermissive temperature at 40°C for 24 h. 5 min after release from nonpermissive temperature, the cells were fixed and double labeled with rabbit 
anti-p125A and mouse anti-Sec31A antibodies. The bottom panels represent the enlarged view of the boxed area in the top panels. The merged images 
are shown in d and h. Arrowheads indicate colocalization of p125A, Sec31A, and VSVG-tsO45-YFP. Bar, 10 µm. (B) HeLa cells were transfected twice 
with ON-Targetplus SMARTpool siRNA (Thermo Fisher Scientific) against p125A or nontarget control. 48 h after the initial transfection, the cells were 
transfected again to express VSVG-tsO45-YFP at 40°C overnight. At 72 h, the cells were released from 40°C block and incubated at 32°C for various times 
as indicated. Cells were then processed to view VSVG-tsO45-YFP. Bar, 10 µm. (C) VSVG-tsO45-YFP acquisition of Endo H resistance is delayed in p125A 
knockdown cells. HeLa cells silenced of p125A were transfected with VSVG tsO45-YFP plasmid and incubated at 40°C overnight. To allow VSVG-tsO45-
YFP transport, the cells were shifted to 32°C. At the indicated times, cell lysate was prepared and subjected to Endo H treatment followed by SDS-PAGE 
and immunoblotting. R and S denote Endo H–resistant and Endo H–sensitive forms, respectively. The ratio (percentage) of the amount of Endo H–resistant 
form to that of the total amount (Endo H–resistant + Endo H–sensitive form) was plotted below. Green solid line represents kinetics of acquisition of VSVG 
tsO45-YFP in nontarget siRNA-treated cells and red dashed lines indicated that in p125A-silenced cells. (D) Secretion of secreted alkaline phosphatase 
(SEAP) is retarded in p125A-silenced cells. HEK293 cells stably expressing SEAP were transfected with ON-Targetplus SMARTpool siRNA (Thermo Fisher 
Scientific) for p125A or nontarget control as described in Materials and methods. 72 h after the initial transfection, the cells were washed five times with 
fresh media (prewarmed to 37°C) and allowed to secrete for various times. Volumes equivalent to 10% of the media were collected at 0, 15, 30, 45, 60, 
90, and 120 min. After 120 min, the cells were washed twice with PBS and lysed with 1X SDS sample buffer. 2% cell lysate were analyzed by SDS-PAGE, 
and then subjected to immunoblot analysis using antibodies against p125A and actin. The collected media was subjected to Chemiluminescent SEAP Assay 
as described by manufacturer (Takara Bio Inc.) to quantify the amount of SEAP present. The results were then normalized by actin and plotted against time. 
The experiment was repeated three times. P < 0.0001. Molecular size markers are in kD.11 of 15 p125 as part of Sec13/Sec31 subcomplex in ER-Golgi transport • Ong et al.
p125A  with  COPII  in  the  ERES  is  extensive.  Furthermore,   
exogenous p125A-Cherry and Sec31A-GFP, when coexpressed, 
displayed almost complete colocalization in structures charac-
teristic of the ERES in both fixed and live cells. Third, export of 
ER-accumulated GT-GFP as well as VSVG-tsO45-YFP was 
significantly delayed when endogenous p125A expression was 
knocked down, whereas post-ER export steps seemed less   
affected. In support of this notion was the observation that 
VSVG-tsO45-YFP was colocalized with Sec31A and p125A 
at structures characteristic of ERES during export. The ability 
of p125A to interact with Sec31A as well as Sec23A is also 
most consistent with a role of p125A to act together with COPII 
coat in ER export.
Although  the  molecular  mechanism  underlying  p125A   
action needs further studies, one hypothesis is that it could fa-
cilitate the coordination and interaction of the Sec31A/Sec13 
subcomplex with the Sec23A/Sec24 subcomplex during the se-
quential recruitment of different COPII components onto the 
membrane of ERES (Fig. 8). Because the binding sites for Sec23A 
and  Sec31A  are  mapped  to  residues  135–259  and  260–600,   
respectively, it is possible that p125A can interact simulta-
neously with both Sec31A and Sec23A at the membrane. Be-
cause the majority of p125A exists in complex with Sec31A/Sec13 
in the cytosol that is clearly distinct from the complex containing 
Sec23A, p125A appears not to interact with Sec23A in the cytosol. 
This is consistent with the observation that immunoprecipitation 
of p125A did not significantly and proportionally co-deplete 
Sec23A. However, coimmunoprecipitation of Sec23A with 
p125A is efficient and robust using total cell lysate (Fig. 2 D). 
Therefore, it seems likely that during recruitment of p125A/
Sec31A/Sec13  heterohexamer  onto  the  membrane-bound 
Sec23A/Sec24 subcomplex, a conformational change may allow 
p125A  to  bind  simultaneously  with  Sec23A  and  Sec31A  to 
strengthen the interaction between these two COPII subcom-
plexes to facilitate the formation of COPII vesicles. The molecu-
lar  structure  of  the  complete  COPII  cage  containing  both 
Sec23/Sec24 and Sec13/Sec31 subcomplexes was recently 
solved using purified COPII proteins (Stagg et al., 2008). This 
self-assembled COPII cage appears to have three layers. The inner-
most layer, which lacks a regular structure, was suggested to 
contain unassembled Sec13/Sec31 and/or the Sec23/Sec24 sub-
complexes. The middle layer comprises the Sec23/Sec24 sub-
complex and the outer layer is made up of the Sec13/Sec31 
subcomplex. The outer layer did not appear to contact the mem-
brane directly but was membrane bound via interaction(s) with 
the inner coat (Matsuoka et al., 2001; Lee and Miller, 2007; Stagg 
et al., 2008). In this context, p125A may potentially strengthen 
the interaction between the inner and outer layers.
A recent study showed that phosphatidylinositol 4-phosphate 
can induce the recruitment of the Sec23/Sec24 subcomplex to the 
membrane by Sar1 in an ATP-independent manner, suggesting that 
phospholipids have an active role to play in the recruitment of   
COPII  components  onto  the  ERES  (Blumental-Perry  et  al., 
2006). p125A contains a phospholipase A1–like domain (Tani   
et al., 1999) and was found to bind phosphatidylinositol phosphate 
(Iinuma et al., 2007). It was previously proposed that the phospho-
lipase homology domain of p125A is a primary determinant for 
and its N-linked glycans become resistant to cleavage by Endo H 
upon its delivery to the Golgi apparatus. As shown in Fig. 7 C,   
for control cells (top panel), a significant amount of VSVG-YFP 
became Endo H resistant at 30 min upon release, and more than 
half of it became Endo H resistant at 60 min. At 90 and 120 min, 
most of VSVG-tsO45-YFP was resistant to Endo H. However, the 
acquisition of Endo H resistance by VSVG-tsO45-YFP was sig-
nificantly delayed when p125A was knocked down (bottom panel). 
In addition, secretion of secreted alkaline phosphatase (SEAP) 
was also retarded when p125A was knocked down (Fig. 7 D), fur-
ther supporting a role of p125A in the secretory pathway.
Differential centrifugation was performed to determine if 
p125A is important for membrane association of Sec13/Sec31 
heterotetramer (Fig. 8 A). Cytosolic and membrane fractions 
were obtained from control and p125A knockdown cells and 
assessed by immunoblot. Syn6 (Bock et al., 1997) and RhoGDI 
(Fukumoto et al., 1990) were used as the marker for the mem-
brane and cytosol, respectively. The majority of Sec13 and 
Sec31A were distributed to the membrane fractions in the non-
target siRNA control cells. In p125A-silenced cells (Fig. 8 A), 
almost 40% of Sec13 and Sec31A was distributed to the cytosol 
as compared with the 5% in the control cells, indicating the im-
portance of p125A in membrane association of Sec13/Sec31.
Discussion
Although p125A was originally identified as an interacting 
partner for Sec23A (Tani et al., 1999; Mizoguchi et al., 2000; 
Nakajima et al., 2002; Shimoi et al., 2005), our present study has 
revealed that the majority of cytosolic p125A is actually in com-
plex with the Sec31A/Sec13 subcomplex. This conclusion is 
based on several observations. First, the majority of endogenous 
p125A cofractionated with Sec31A and Sec13 by gel filtration 
analysis as a protein complex with a size of 600–700 kD.   
Second, exhaustive, quantitative immunoprecipitations of HA-
p125A using anti-HA antibody can effectively and proportionally 
co-deplete endogenous Sec31A as well as total p125A (the latter 
consisting of HA-p125A as well as endogenous p125A). Third, 
HA-p125 and myc-p125A can be both coimmunoprecipitated, 
together with Sec31A with either anti-HA or anti-myc antibodies. 
Coimmunoprecipitation of HA-p125 by anti-myc antibody   
is dependent on the coexpression of myc-p125A or vice versa, 
suggesting that p125A could potentially form homodimers or 
oligomers. Because Sec31A/Sec13 exists as heterotetramer and 
the complex containing p125A, Sec31A, and Sec13 has a size of 
600–700 kD, we favor a model in which p125A, Sec31A, and 
Sec13 form a heterohexameric complex with two molecules of 
each in the cytosol, resulting in an estimated size of 600 kD. 
Future work using techniques like cryoelectron microscopy will 
be needed to gain additional insight into this possibility.
The cellular role of p125A is most consistent with it being 
an accessory protein for COPII components to facilitate ER ex-
port from the ERES. This conclusion is based on several lines of 
evidence. First, the majority of p125A exists as part of the pre-
existing Sec31A/Sec13 subcomplex in the cytosol as mentioned. 
Second, p125A is enriched in the ERES marked by COPII com-
ponents such as Sec31A. The colocalization of endogenous JCB   12 of 15
Knockdown of p125A also caused the Golgi apparatus to 
fragment into many mini-Golgi structures containing markers of 
cis-, medial-, and trans-subcompartments, which suggest that the 
cis-trans organization is preserved, whereas stacking or fusion of 
these structures into compact Golgi ribbons is compromised. Al-
though a direct role for p125A in maintaining the Golgi structure 
cannot be excluded, we favor the possibility that the observed 
membrane attachment (Tani et al., 1999, Shimoi et al., 2005), 
while the N-terminal region that interacts with Sec23A coordinates 
membrane  specificity  (Mizoguchi  et  al.,  2000).  In  this  regard, 
p125A may also facilitate and strengthen the interaction of COPII 
components with membrane lipids. Studies along these lines will 
definitely offer new insights into the detailed mechanism of action 
of p125A and COPII-mediated export at the ERES in general.
Figure 8.  p125A stabilizes the Sec13/Sec31 
heterotetramer to the ERES membrane. (A) Mem-
brane (m) and cytosol (c) fractions were ob-
tained  from  cells  transfected  with  siRNA. 
Equivalent amounts of each fraction were sub-
jected to SDS-PAGE followed by immunoblot 
analysis.  Molecular  size  markers  are  in  kD. 
The  intensities  of  the  bands  were  quantified 
using  Quantity  One  software  (Bio-Rad  Labo-
ratories).  The  ratio  of  distribution  is  relative 
to  the  total.  Total  =  m  (membrane  fraction) 
+ c (cytosol fraction). Ratio = m or c/(m+c). 
The  experiment  was  repeated  three  times;   
*, P < 0.05. Syntaxin 6 (Syn6) was used as 
the marker for the membrane fraction and the 
Rho GDP dissociation inhibitor (RhoGDI) was 
used as the marker for the cytosolic fraction.   
(B) A working model to illustrate the role of 
p125A in ER export in mammalian cells. The 
majority of p125A, Sec31A, and Sec13 likely 
exists in the form of a heterohexamer. Upon 
recruitment of Sar1 and Sec23A/Sec24 sub-
complex  during  COPII  vesicle  budding,  the 
p125A/Sec31A/Sec13  subcomplex  is  then 
recruited,  which  may  open  up  the  binding 
site of p125A for Sec23A. The simultaneous 
interaction of p125A with both Sec31A and 
Sec23A on the budding vesicles may facilitate 
the coordination of these two COPII subcom-
plexes to mediate vesicle formation.13 of 15 p125 as part of Sec13/Sec31 subcomplex in ER-Golgi transport • Ong et al.
Molecular Cell Biology, Singapore). 293 cells were grown in DME supple-
mented with 10% fetal bovine serum (FBS; Hyclone). All HeLa cell lines were 
cultured  in  DME-low  glucose  (1000  mg/L  d-glucose)  supplemented  with 
10% FBS and 2 mM l-glutamine (Sigma-Aldrich). HeLa GT-GFP and HeLa 
ManII-GFP were cultured in the presence of 0.4 mg/ml of G418 (Invitrogen). 
Cells were cultured at 37°C with 5% CO2 and 95% humidity.
Other materials
The YFP expressed as fusion with VSVG tsO45 (VSVG-tsO45-YFP) was a gift 
from Dr. Alexander Mironov (Consorzio Mario Negri Sud, Chieti, Italy). 
KIAA clones were provided by the Kazusa DNA Research Institute (Chiba, 
Japan).  Expressed  sequence  tag  (EST)  clone(s)  was  obtained  from  the   
I.M.A.G.E. consortium via Invitrogen. Brefeldin A (BFA) was purchased from 
Epicentre Biotechnologies.
Gel filtration
HeLa cytosol was fractionated using the Superose 6 HR 10/30 column 
(GE Healthcare), using the ÄKTA Purifier 10 FPLC system (GE Health-
care). Fractionation was performed in 25/125 buffer (25 mM Hepes,   
pH 7.2, and 125 mM potassium acetate) containing 1 mM PMSF at 4°C. 
Flow rate was 0.3 ml/min and fractions of 0.6 ml each were collected. 
The fractions were precipitated with trichloroacetic acid (TCA), resolved 
by SDS-PAGE, and transferred to PVDF membrane (Millipore) for subse-
quent immunodetection.
Transfection and gene silencing
All plasmid transfections were performed using Effectene (QIAGEN). All 
siRNA duplexes were of the ON-TARGETplus SMARTpool type obtained 
from Thermo Fisher Scientific. siRNA duplexes were transfected into HeLa 
cells using Oligofectamine transfection reagent (Invitrogen) according to the 
manufacturer’s protocol. For efficient expression knockdown, the cells were 
transfected twice with a 24-h interval. All experiments were performed 72 h 
after the first siRNA transfection.
Preparation of cytosol and membrane fractions
Cells were harvested and homogenized in cytosol buffer (20 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, and 1 mM PMSF with complete EDTA-free prote-
ase  inhibitor  mixture  [from  Roche]).  The  cell  suspension  was  passed 
through a 29G needle 10 times on ice. The cell lysate was briefly centri-
fuged at 2,000 rpm for 5 min at 4°C. The clarified lysate was then sub-
jected to centrifugation at 85,000 rpm using the TLA120.1 rotor (Beckman 
Coulter) for 1 h at 4°C. Cytosol was collected and the membrane pellet 
was washed once with cytosol buffer and then centrifuged at 85,000 rpm 
for 30 min at 4°C once more using the TLA120.1 rotor. The membrane 
pellet was resuspended in lysis buffer and centrifuged again at 85,000 
rpm using the TLA120.1 rotor for 1 h at 4°C for the third time. The solubi-
lized membrane proteins were then collected. The proteins were resolved 
by SDS-PAGE and transferred to PVDF membrane (Millipore) for subse-
quent immunodetection.
Immunoprecipitation
Cells on tissue culture dishes were lysed in lysis buffer (20 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1% Triton X-100, and 1 mM PMSF with com-
plete EDTA-free protease inhibitor mixture [Roche]). The lysate was incu-
bated on ice for 30 min and cleared by centrifugation at 13,000 rpm 
for 30 min at 4°C. Immunoprecipitation was performed at 4°C with 5 µg 
of antibody in the presence of either protein A– or protein G–Sepharose 4   
Fast Flow (GE Healthcare) for 4 h at 4°C with rotation. The Sepharose 
was then washed five times with cell lysis buffer and twice with cold PBS. 
Bound proteins were eluted with 2x Laemmli sample buffer, resolved by 
SDS-PAGE,  and  transferred  to  PVDF  membrane  (Millipore)  for  subse-
quent immunodetection.
Fluorescence microscopy
Cells grown on coverslips (Thermo Fisher Scientific) were washed two times 
with PBS supplemented with 1 mM CaCl2 and 1 mM MgCl2 (PBSCM). The 
cells were then fixed with 4% paraformaldehyde in PBSCM for 20 min at 
room temperature. The fixed cells were washed five times at 5-min intervals 
using PBSCM and then permeabilized with 0.1% Saponin (Sigma-Aldrich) 
in PBSCM for 20 min at room temperature. The cells were then immuno-
labeled with appropriate primary antibodies diluted in fluorescence dilution 
buffer (FDB; PBSCM with 5% FBS and 2% bovine serum albumin [BSA]) for 
1 h at room temperature. The coverslips were then washed five times with 
0.1% Saponin PBSCM at 5-min intervals. Secondary antibodies were di-
luted appropriately in FDB and incubated at room temperature for 1 h. The 
coverslips were washed again with 0.1% Saponin PBSCM five times at   
Golgi fragmentation and dispersion is an indirect consequence of 
delayed ER export of some cargo proteins that are important to 
establish and maintain the compact Golgi structure. Consistent 
with this notion was the observation that knockdown of Sec13 re-
sulted in a similar and more profound fragmentation and disper-
sion of the Golgi apparatus. Earlier studies have also shown that 
depletion of tethering factors and SNAREs that are involved in 
ER-to-Golgi transport also caused fragmented Golgi structures 
(Lu et al., 2004; Suga et al., 2005; Marra et al., 2007; Satoh and 
Warren, 2008; Iinuma et al., 2009). This is also in agreement with 
the observation that the continual influx of proteins and mem-
brane from the ER to the Golgi is essential for the maintenance of 
the Golgi ribbon (Shorter and Warren, 1999; Zolov and Lupashin, 
2005). Therefore, delayed ER export and reduced anterograde 
transport from the ER to the Golgi in response to p125A silencing 
may be the basis for the observed alterations in Golgi morphol-
ogy. Several studies have shown that even though the integrity of 
the Golgi was affected in a similar way, secretory cargo could still 
be delivered to the Golgi complex and beyond, albeit with a lower 
efficiency (Kondylis and Rabouille, 2003; Marra et al., 2007; 
Diao et al., 2008). Consistently, we have observed that VGSG 
transport to the cell surface still occurred when p125A was si-
lenced, although the ER export step was clearly delayed. Collec-
tively, these results suggest that the primary role of p125A is likely 
one that is within the context of COPII-mediated vesicle budding 
to facilitate efficient export of cargo proteins from the ERES.
Results of our p125A siRNA knockdown seem to differ 
from what was reported by Shimoi et al. (2005). They did not 
observe any significant delay in protein export in p125A-silenced 
cells, whereas we showed that protein export was delayed. To ad-
dress the discrepancy, we have performed knockdown experi-
ments using their siRNA and transfection condition. Efficient 
knockdown was seen in only a fraction of cells in which the 
Golgi apparatus was dispersed, whereas the Golgi apparatus was 
not significantly affected in surrounding cells that still had de-
tectable levels of p125A (Fig. S1 B, e–h). Using our double-
transfection protocol with their siRNA (at higher concentration), 
more robust knockdown was achieved and the Golgi apparatus 
was dispersed in most cells (Fig. S1 B, m–p). Similar results 
were observed when the reassembly of the Golgi apparatus was 
assessed in response to BFA treatment and washout (Fig. S2). 
Therefore, the seemingly contradicting results were likely due to 
the difference in knockdown efficiency of p125A.
Materials and methods
Antibodies
Antibodies were from the following sources: Actin, myc, and HA (Santa 
Cruz Biotechnology, Inc.); GM130, Rab8, and Sec31A (BD); Syn5 (Synap-
tic  Systems  GmbH);  Giantin  and  Sec23A  (Abcam);  Sec13A  (Abnova);   
-tubulin and Flag (Sigma-Aldrich); and VSVG (Bethyl Laboratories, Inc.). 
Fluorochrome-conjugated secondary antibodies were from Invitrogen and 
HRP-conjugated secondary antibodies were from Jackson ImmunoResearch 
Laboratories, Inc.
Cell lines
HEK293 and HeLa cells were obtained from American Type Culture Collec-
tion (Manassas, VA). HeLa cells stably expressing GT-GFP were a gift from 
Dr. Jack Rohrer (Friedrich Miescher Institut, Basel, Switzerland). HeLa cells 
stably expressing ManII-GFP was a gift from Dr. Frederic Bard (Institute of JCB   1 of 15
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VSVG transport assay
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Quantitation of Golgi dispersion
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Therefore, the further the distance from the relative center of the Golgi, the 
greater the degree of Golgi dispersion.
Online supplemental material
Fig. S1 shows that different siRNA transfection protocols affect the effi-
ciency of p125A knockdown in HeLa cells. Fig. S2 shows that Golgi 
reassembly  after  BFA  treatment  and  washout  was  delayed  in  p125A-
silenced  cells.  Video  1  shows  that  p125A-Cherry  and  Sec31A-GFP 
colocalize stably in vesicular structures that appear to undergo homo-
typic fusion. Video 2 shows a magnified view of Video 1 up to 30 min. 
Online supplemental material is available at http://www.jcb.org/cgi/ 
content/full/jcb.201003005/DC1.
We thank Dr. Alexander Mironov for providing the VSVG-tsO45-YFP construct, 
Dr. Jack Rohrer for HeLa GT-GFP cells, and Dr. Frederic Bard for HeLa ManII-
GFP cells. The KIAA clones were provided by the Kazusa DNA Research Insti-
tute. We thank Mr. Raphael Ong for his help in the cloning of fluorescent 
protein-fused p125A and Sec31A.
Submitted: 1 March 2010
Accepted: 14 July 201015 of 15 p125 as part of Sec13/Sec31 subcomplex in ER-Golgi transport • Ong et al.
Shugrue, C.A., E.R. Kolen, H. Peters, A. Czernik, C. Kaiser, L. Matovcik, A.L. 
Hubbard, and F. Gorelick. 1999. Identification of the putative mamma-
lian orthologue of Sec31P, a component of the COPII coat. J. Cell Sci. 
112:4547–4556.
Siegel, L.M., and K.J. Monty. 1966. Determination of molecular weights and 
frictional ratios of proteins in impure systems by use of gel filtration and 
density gradient centrifugation. Application to crude preparations of sul-
fite and hydroxylamine reductases. Biochim. Biophys. Acta. 112:346–362. 
doi:10.1016/0926-6585(66)90333-5
Stagg, S.M., C. Gürkan, D.M. Fowler, P. LaPointe, T.R. Foss, C.S. Potter, B. 
Carragher, and W.E. Balch. 2006. Structure of the Sec13/31 COPII coat 
cage. Nature. 439:234–238. doi:10.1038/nature04339
Stagg, S.M., P. LaPointe, A. Razvi, C. Gürkan, C.S. Potter, B. Carragher, and 
W.E. Balch. 2008. Structural basis for cargo regulation of COPII coat   
assembly. Cell. 134:474–484. doi:10.1016/j.cell.2008.06.024
Stankewich, M.C., P.R. Stabach, and J.S. Morrow. 2006. Human Sec31B: a fam-
ily of new mammalian orthologues of yeast Sec31p that associate with the 
COPII coat. J. Cell Sci. 119:958–969. doi:10.1242/jcs.02751
Suga,  K.,  H.  Hattori, A.  Saito,  and  K. Akagawa.  2005.  RNA  interference-
mediated  silencing  of  the  syntaxin  5  gene  induces  Golgi  fragmenta-
tion but capable of transporting vesicles. FEBS Lett. 579:4226–4234. 
doi:10.1016/j.febslet.2005.06.053
Supek, F., D.T. Madden, S. Hamamoto, L. Orci, and R. Schekman. 2002. Sec16p 
potentiates the action of COPII proteins to bud transport vesicles. J. Cell 
Biol. 158:1029–1038. doi:10.1083/jcb.200207053
Tang,  B.L., T.  Zhang,  D.Y.  Low,  E.T. Wong,  H.  Horstmann,  and W.  Hong. 
2000.  Mammalian  homologues  of  yeast  sec31p. An  ubiquitously  ex-
pressed form is localized to endoplasmic reticulum (ER) exit sites and 
is essential for ER-Golgi transport. J. Biol. Chem. 275:13597–13604. 
doi:10.1074/jbc.275.18.13597
Tani, K., T. Mizoguchi, A. Iwamatsu, K. Hatsuzawa, and M. Tagaya. 1999. p125 
is a novel mammalian Sec23p-interacting protein with structural similar-
ity to phospholipid-modifying proteins. J. Biol. Chem. 274:20505–20512. 
doi:10.1074/jbc.274.29.20505
Velasco,  A.,  L.  Hendricks,  K.W.  Moremen,  D.R.  Tulsiani,  O.  Touster,  and 
M.G. Farquhar. 1993. Cell type-dependent variations in the subcellu-
lar distribution of alpha-mannosidase I and II. J. Cell Biol. 122:39–51. 
doi:10.1083/jcb.122.1.39
Zolov, S.N., and V.V. Lupashin. 2005. Cog3p depletion blocks vesicle-mediated 
Golgi retrograde trafficking in HeLa cells. J. Cell Biol. 168:747–759. 
doi:10.1083/jcb.200412003
Skb15, a highly conserved inhibitor of the fission yeast PAK, Shk1. Mol. 
Cell. 7:1095–1101. doi:10.1016/S1097-2765(01)00248-9
Kirk, S.J., and T.H. Ward. 2007. COPII under the microscope. Semin. Cell Dev. 
Biol. 18:435–447. doi:10.1016/j.semcdb.2007.07.007
Kondylis, V., and C. Rabouille. 2003. A novel role for dp115 in the organiza-
tion of tER sites in Drosophila. J. Cell Biol. 162:185–198. doi:10.1083/ 
jcb.200301136
Kuehn, M.J., J.M. Herrmann, and R. Schekman. 1998. COPII-cargo interac-
tions direct protein sorting into ER-derived transport vesicles. Nature. 
391:187–190. doi:10.1038/34438
Kuge, O., C. Dascher, L. Orci, T. Rowe, M. Amherdt, H. Plutner, M. Ravazzola, 
G. Tanigawa, J.E. Rothman, and W.E. Balch. 1994. Sar1 promotes vesicle 
budding from the endoplasmic reticulum but not Golgi compartments.  
J. Cell Biol. 125:51–65. doi:10.1083/jcb.125.1.51
Lederkremer, G.Z., Y. Cheng, B.M. Petre, E. Vogan, S. Springer, R. Schekman, 
T. Walz, and T. Kirchhausen. 2001. Structure of the Sec23p/24p and 
Sec13p/31p complexes of COPII. Proc. Natl. Acad. Sci. USA. 98:10704–
10709. doi:10.1073/pnas.191359398
Lee, M.C., and E.A. Miller. 2007. Molecular mechanisms of COPII vesicle 
formation.  Semin.  Cell  Dev.  Biol.  18:424–434.  doi:10.1016/j.semcdb 
.2007.06.007
Lee, M.C., E.A. Miller, J. Goldberg, L. Orci, and R. Schekman. 2004. Bi-directional 
protein transport between the ER and Golgi. Annu. Rev. Cell Dev. Biol. 
20:87–123. doi:10.1146/annurev.cellbio.20.010403.105307
Lu, L., G. Tai, and W. Hong. 2004. Autoantigen Golgin-97, an effector of Arl1 
GTPase, participates in traffic from the endosome to the trans-golgi net-
work. Mol. Biol. Cell. 15:4426–4443. doi:10.1091/mbc.E03-12-0872
Mancias, J.D., and J. Goldberg. 2005. Exiting the endoplasmic reticulum. Traffic. 
6:278–285. doi:10.1111/j.1600-0854.2005.00279.x
Marra, P., L. Salvatore, A. Mironov Jr., A. Di Campli, G. Di Tullio, A. Trucco, G. 
Beznoussenko, A. Mironov, and M.A. De Matteis. 2007. The biogenesis 
of the Golgi ribbon: the roles of membrane input from the ER and of 
GM130. Mol. Biol. Cell. 18:1595–1608. doi:10.1091/mbc.E06-10-0886
Matsuoka, K., L. Orci, M. Amherdt, S.Y. Bednarek, S. Hamamoto, R. Schekman, 
and T. Yeung. 1998. COPII-coated vesicle formation reconstituted with 
purified coat proteins and chemically defined liposomes. Cell. 93:263–
275. doi:10.1016/S0092-8674(00)81577-9
Matsuoka, K., R. Schekman, L. Orci, and J.E. Heuser. 2001. Surface structure of 
the COPII-coated vesicle. Proc. Natl. Acad. Sci. USA. 98:13705–13709. 
doi:10.1073/pnas.241522198
Mizoguchi,  T.,  K.  Nakajima,  K.  Hatsuzawa,  M.  Nagahama,  H.P.  Hauri,  M. 
Tagaya, and K. Tani. 2000. Determination of functional regions of p125, 
a novel mammalian Sec23p-interacting protein. Biochem. Biophys. Res. 
Commun. 279:144–149. doi:10.1006/bbrc.2000.3846
Nakajima, K., H. Sonoda, T. Mizoguchi, J. Aoki, H. Arai, M. Nagahama, M. 
Tagaya, and K. Tani. 2002. A novel phospholipase A1 with sequence ho-
mology to a mammalian Sec23p-interacting protein, p125. J. Biol. Chem. 
277:11329–11335. doi:10.1074/jbc.M111092200
Nakano, A., and M. Muramatsu. 1989. A novel GTP-binding protein, Sar1p, is 
involved in transport from the endoplasmic reticulum to the Golgi appara-
tus. J. Cell Biol. 109:2677–2691. doi:10.1083/jcb.109.6.2677
Saito-Nakano, Y., and A. Nakano. 2000. Sed4p functions as a positive regulator 
of Sar1p probably through inhibition of the GTPase activation by Sec23p. 
Genes Cells. 5:1039–1048. doi:10.1046/j.1365-2443.2000.00391.x
Salama, N.R., T. Yeung, and R.W. Schekman. 1993. The Sec13p complex and 
reconstitution of vesicle budding from the ER with purified cytosolic pro-
teins. EMBO J. 12:4073–4082.
Salama, N.R., J.S. Chuang, and R.W. Schekman. 1997. Sec31 encodes an essen-
tial component of the COPII coat required for transport vesicle budding 
from the endoplasmic reticulum. Mol. Biol. Cell. 8:205–217.
Satoh, A., and G. Warren. 2008. In situ cleavage of the acidic domain from the 
p115 tether inhibits exocytic transport. Traffic. 9:1522–1529. doi:10.1111/
j.1600-0854.2008.00783.x
Schaub, B.E., B. Berger, E.G. Berger, and J. Rohrer. 2006. Transition of galac-
tosyltransferase 1 from trans-Golgi cisterna to the trans-Golgi network 
is  signal  mediated.  Mol.  Biol.  Cell.  17:5153–5162.  doi:10.1091/mbc 
.E06-08-0665
Shaywitz, D.A., P.J. Espenshade, R.E. Gimeno, and C.A. Kaiser. 1997. COPII 
subunit interactions in the assembly of the vesicle coat. J. Biol. Chem. 
272:25413–25416. doi:10.1074/jbc.272.41.25413
Shimoi, W., I. Ezawa, K. Nakamoto, S. Uesaki, G. Gabreski, M. Aridor, A. 
Yamamoto, M. Nagahama, M. Tagaya, and K. Tani. 2005. p125 is local-
ized in endoplasmic reticulum exit sites and involved in their organiza-
tion. J. Biol. Chem. 280:10141–10148. doi:10.1074/jbc.M409673200
Shorter, J., and G. Warren. 1999. A role for the vesicle tethering protein, p115, 
in the post-mitotic stacking of reassembling Golgi cisternae in a cell-free 
system. J. Cell Biol. 146:57–70.